In:
Digestion, S. Karger AG, Vol. 75, No. 2-3 ( 2007), p. 104-112
Abstract:
〈 i 〉 Background/Aims: 〈 /i 〉 To evaluate the long-term outcome of surgical and non-surgical local treatments of patients with hepatocellular carcinoma (HCC). 〈 i 〉 Methods: 〈 /i 〉 We stratified a cohort of 278 HCC patients using six independent predictors of survival according to the Vienna survival model for HCC (VISUM-HCC). 〈 i 〉 Results: 〈 /i 〉 Prior to therapy, 224 HCC patients presented with VISUM stage 1 (median survival 18 months) while 29 patients were classified as VISUM stage 2 (median survival 4 months) and 25 patients as VISUM stage 3 (median survival 3 months). A highly significant (p 〈 0.001) improved survival time was observed in VISUM stage 1 patients treated with liver resection (n = 52; median survival 37 months) or chemoembolization (TACE) and subsequent radiofrequency ablation (RFA) (n = 44; median survival 45 months) as compared to patients receiving chemoembolization alone (n = 107; median survival 13 months) or patients treated by tamoxifen only (n = 21; median survival 6 months). Chemoembolization alone significantly (p ≤ 0.004) improved survival time in VISUM stage 1–2 patients but not (p = 0.341) in VISUM stage 3 patients in comparison to those treated by tamoxifen. 〈 i 〉 Conclusion: 〈 /i 〉 Both liver resection or combined chemoembolization and RFA improve markedly the survival of patients with HCC.
Type of Medium:
Online Resource
ISSN:
0012-2823
,
1421-9867
Language:
English
Publisher:
S. Karger AG
Publication Date:
2007
detail.hit.zdb_id:
1482218-0